- Home
- MBRX vs WINT Comparison
MBRX vs WINT Comparison
Compare MBRX & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- WINT
- Stock Information
- Founded
- MBRX 2015
- WINT 1992
- Country
- MBRX United States
- WINT United States
- Employees
- MBRX N/A
- WINT N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBRX Health Care
- WINT Health Care
- Exchange
- MBRX Nasdaq
- WINT Nasdaq
- Market Cap
- MBRX 1.4M
- WINT 1.5M
- IPO Year
- MBRX 2016
- WINT 1995
- Fundamental
- Price
- MBRX $1.28
- WINT $4.35
- Analyst Decision
- MBRX Strong Buy
- WINT Hold
- Analyst Count
- MBRX 2
- WINT 1
- Target Price
- MBRX $24.00
- WINT $350.00
- AVG Volume (30 Days)
- MBRX 13.3M
- WINT 350.4K
- Earning Date
- MBRX 03-21-2025
- WINT 04-15-2025
- Dividend Yield
- MBRX N/A
- WINT N/A
- EPS Growth
- MBRX N/A
- WINT N/A
- EPS
- MBRX N/A
- WINT N/A
- Revenue
- MBRX N/A
- WINT N/A
- Revenue This Year
- MBRX N/A
- WINT N/A
- Revenue Next Year
- MBRX N/A
- WINT N/A
- P/E Ratio
- MBRX N/A
- WINT N/A
- Revenue Growth
- MBRX N/A
- WINT N/A
- 52 Week Low
- MBRX $0.40
- WINT $3.93
- 52 Week High
- MBRX $6.24
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- MBRX 46.92
- WINT 24.74
- Support Level
- MBRX $1.55
- WINT $5.70
- Resistance Level
- MBRX $2.22
- WINT $10.79
- Average True Range (ATR)
- MBRX 0.50
- WINT 1.20
- MACD
- MBRX 0.08
- WINT 0.20
- Stochastic Oscillator
- MBRX 27.12
- WINT 6.13
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.